Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer

INTRODUCTION: The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to cause mineralocorticoid excess syndrome characteri...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Case Rep Urol
Egile Nagusiak: Yamamoto, Yutaka, Akashi, Yasunori, Minami, Takahumi, Nozawa, Masahiro, Kiba, Keisuke, Yoshikawa, Motokiyo, Hirayama, Akihide, Uemura, Hirotsugu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2018
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6165612/
https://ncbi.nlm.nih.gov/pubmed/30305978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/1414395
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak